Modelling the efficacy of Neprilysin from various species in degrading different Amyloid-β peptides: Potential application in therapeutics of Alzheimer’s disease

Abstract

Recombinant neprilysin due to its degradation potential against Amyloid-beta (A-beta) peptides has been looked at as a potential therapeutic candidate for treating Alzheimers disease (AD). However the enzymatic activity of neprilysin against different Aβ peptides can variable which significantly limits the therapeutic optimization. Using the molecular interaction analysis and modelling it against the known enzyme-substrate kinetics, this study developed a novel approach to predicting biosimilar enzyme-substrate kinetics. The known enzyme-substrate kinetics of human recombinant neprilysin with A-beta1-40 peptide was used as the prototype to assess the affinity and efficacy of various inter and intra-species neprilysin- A-beta peptide enzyme kinetics based on the relative molecular interaction analysis. Significant inter and intra-species variations in neprilysin- A-beta peptide enzyme kinetics was observed which further validated the need for optimizing enzyme kinetics tailored to specific substrate degradation. The novel enzyme kinetics modelling approach described in this study can be helpful in the developing of recombinant enzymes/peptides for personalised therapeutic applications.

Network Pharmacology Analysis of Orally Bioavailable SARS-CoV-2 Protease Inhibitor Shows Synergistic Targets to Improve Clinical Efficacy

“…[12][13][14][15] The reported affinity of homologous structure of PF32 with Fibroblast activation protein alpha (PDB ID IZ68) was used as reference and the affinity of the PF32 with its identified targets was predicted based on the differences in the ratio of hydrogen bonds compared to that of the reference standard as reported before. 7,12,16 In similar lines the affinity of PF32 against SARS-CoV-2 targets was also estimated as reported before. 12,16 BEMS Reports, Vol 7, Issue 2, Jul-Dec, 2021…”

“…7,12,16 In similar lines the affinity of PF32 against SARS-CoV-2 targets was also estimated as reported before. 12,16 BEMS Reports, Vol 7, Issue 2, Jul-Dec, 2021…”